- Design
- Retrospective national cohort, claims linked to laboratory results
- Population
- 27,650 US adults with laboratory-confirmed diabetes and no prior diabetes record
- Primary outcome
- Type 2 diabetes diagnostic coding and drug treatment within one year
- Effect
- Both 66.6%; code only 19.7%; treatment only 4.1%; neither 9.6%
Researchers linked US commercial and Medicare claims from 2017 to 2023 with laboratory results and followed 27,650 adults whose results met diabetes criteria and who had no prior diabetes or prediabetes record.
Within a year, 66.6% had both a type 2 diabetes code and drug treatment. 19.7% had a code only, 4.1% treatment only, and 9.6% neither. HbA1c between 6.5% and 6.9% carried the lowest chance of being coded or treated, and higher comorbidity burden was linked to lower chances of both.
Claims data cannot see lifestyle advice or notes that never became a code, so some of these patients may have been managed without drugs. Even so, an uncoded diagnosis tends to miss the annual eye, foot, kidney and lipid checks that follow from a label.
The practical lesson is a systems one: an abnormal HbA1c in a patient seen for something else is easy to lose. Mildly raised values and busy multimorbid patients are where it happens most.
- Act on every HbA1c of 6.5% or above: confirm with a repeat test unless symptoms make it unnecessary
- Record the diagnosis once confirmed, so eye, foot, kidney and lipid checks follow
- Take extra care with patients admitted or seen for another illness, where results are easily overlooked
- Do not treat an HbA1c of 6.5 to 6.9% as too mild to label; early diagnosis opens the window for remission
- Audit your own clinic's raised HbA1c results that have no follow-up plan
Why it matters
The commonest diabetes failure may be the result already in the record that nobody acted on.
Don't overread it
Claims data cannot capture lifestyle advice, so some uncoded or untreated patients may have had appropriate care.
The statistics, in plain English
These are associations from routine data, not a trial. The 9.6% with neither code nor drug is the clearest gap; the 19.7% coded but untreated may include appropriate lifestyle-first care, so not all of the one third is a failure.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free